Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Merck & Co., Inc. (MRK) Price & Performance

Vanguard Total Bond Market Index Fund ETFTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Vanguard Total Bond Market Index Fund ETF vs Merck & Co., Inc. — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.25, while Merck & Co., Inc. trades at $130.29 (market cap $323.00B). The key difference: Merck & Co., Inc. pays a 2.6% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.

BNDMRK
52-Week High
$75.17$131.84
52-Week Low
$72.15$77.60
Market Cap
$323.00B
Sector
Health
Enterprise Value
$369.77B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total Bond Market Index Fund ETF

BND trades at $72.4, up 0.21% today, with a neutral technical signal from indicators like RSI near 50. Recent news highlights institutional activity, including Boston Standard Wealth reducing its stake by 30.6% in Q2 2026 (SEC filing, August 5, 2026), while Arkadios Wealth increased holdings by 41.9% (SEC filing, July 30, 2026). The bond ETF faces headwinds from rising Treasury yields and inflation concerns, as noted in financial media.

Outlook is cautious due to interest rate sensitivity and macroeconomic volatility. Risks include Fed policy shifts and oil price fluctuations, but BND offers diversification and steady dividends, with recent payouts around $0.24-$0.25. Investors should weigh income benefits against bond market pressures.

Merck & Co., Inc.

MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total Bond Market Index Fund ETF

This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.

Read more on BND

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK